Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 6/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.49 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.49 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
| ▸ | DPP4 | P27487 | 2/20 | 0.48 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.48 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.48 |
| ▸ | PEPD | P12955 | 2/20 | 0.47 |
| ▸ | XPNPEP1 | Q9NQW7 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ELANE | P08246 | 6/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15692923 | 0.96 | FKBP1A (0.46) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL239407 | 0.89 | ACE (0.52) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL242197 | 0.89 | ACE (0.52) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL12598148 | 0.89 | ACE (0.52) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL12567110 | 0.89 | ACE (0.52) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL239406 | 0.89 | ACE (0.52) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL12566960 | 0.89 | DPP4 (0.51) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL8352620 | 0.89 | CMA1 (0.51) | PEPDXPNPEP1ELANE | |
| SCHEMBL8169782 | 0.89 | DPP4 (0.43) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL1985159 | 0.89 | ELANE (0.48) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011075607-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2011-06-23 | — | — | WO | disclosed |
| US-20110152246-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152246-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, IRF3 | CYP3A4 1292/4885CYP2C9 3042/4885KCNH2 4483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.